Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study

Table 5

Characteristics of anti-TNFi Ab-negative and -positive rheumatoid arthritis patients in remission.

	Anti-TNFi Ab-negative; = 84 (90%)	Anti-TNFi Ab-positive; = 9 (10%)
Age, years	57 (50–69)	55 (46–66)	0.559
Female gender, (%)	47 (56)	8 (89)	0.077
Seropositivity, (%)	62 (74)	7 (78)	1.000
Duration of biologic therapy, months	60 (35–88)	50 (38–70)	0.413
Remission duration, months	18 (10–33)	17 (16–27)	0.537

Continuous variables are expressed as medians (interquartile ranges).